Adolescents FDA's greatest concern for GSK's Breo in asthma
This article was originally published in Scrip
Executive Summary
The FDA raised several concerns about the use of GlaxoSmithKline's Breo Ellipta (fluticasone furoate/vilanterol inhalation powder) in treating patients 12-17 years as a once daily treatment for asthma, but that may not stop a panel of advisers from recommending its use in adults.